

Reference number(s) 4859-A

# Specialty Guideline Management Rezurock

### **Products Referenced by this Document**

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated

Brand Name	Generic Name
Rezurock	belumosudil

### **Indications**

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### FDA-approved Indications<sup>1</sup>

Rezurock is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy.

All other indications are considered experimental/investigational and not medically necessary.

## **Coverage Criteria**

#### Chronic Graft versus Host Disease (cGVHD)<sup>1</sup>

Authorization of 12 months may be granted for treatment of cGVHD when both of the following criteria are met:

Rezurock SGM 4859-A P2025.docx

© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

- The member has failed two or more lines of systemic therapy
- The member is at least 12 years of age

# **Continuation of Therapy**

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria section when all of the following criteria are met:

- The member does not have evidence of unacceptable toxicity while on the current regimen
- The member has not experienced clinically significant progression of cGVHD (i.e., progression that requires new systemic therapy) while on the current regimen

#### References

1. Rezurock [package insert]. Bridgewater, NJ: Kadmon Pharmaceuticals; April 2024.